upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism

upLIFT: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI)

IDENTIFIER (ClinicalTrials.gov): NCT06881992

DRUG/TREATMENT: Ersodetug

PHASE: 3

STATUS: Recruiting

SPONSOR: Rezolute

DESCRIPTION:

Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug, can safely reduce hypoglycemia in adults with tumor HI.

In tumor HI, certain tumors (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumor that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumor hypoglycemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia”) is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumors can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor. 

Hypoglycemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumor HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care.

This study is open to people 18 and older who have a type of tumor that causes tumor HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov. You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed. Please note that ersodetug is still under investigation and has not been approved by any health authority.  

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to  view this trial here.

CONTACT

Name: Rezolute Clinical Trial

Phone Number: 650-206-4507

Email: patient-affairs@rezolutebio.com (primary contact). You may also reach out to clinicaltrials@rezolutebio.com.

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.